Making a 70% return in only three months sounds pretty good. Three biotech stocks have done just that and more. Shares of Clovis Oncology soared over 120% during the last three months. Bluebird bio’s (NASDAQ:BLUE) stock jumped more than 80% during the period, while shares of Exelixis are up over 70%.
Is it a case of too much too fast for Clovis, Bluebird, and Exelixis? Or are these three scorching hot biotech stocks still buys?
